APOE Gene Suppression with Cold Atmospheric Plasma for Sarcoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for soft tissue sarcoma, such as radiation, en bloc surgical resection, and chemotherapy, fail to eliminate local microscopic tumor cells despite complete surgical excision, necessitating improved methods to enhance treatment efficacy.
Innovation Solution
Utilizing cold atmospheric plasma (CAP) to treat soft tissue sarcoma by reducing sarcoma cell viability in a time- and power-dependent manner, combined with surgical resection and intraoperative radiation, and potentially using a pharmaceutical to suppress apolipoprotein E genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional surgical resection is performed to remove sarcoma tumors, then macroscopic tumor removal is achieved, but local microscopic tumor cells remain undetected and untreated
Solution Approach 1:
Cold atmospheric plasma treatment is applied to surgical margins before or during the time when residual tumor cells might be present, proactively eliminating microscopic disease before it can recur. This preliminary action targets the surgical margins where residual cells are most likely to exist.
Solution Approach 2:
The patent replaces purely mechanical surgical resection with a combination of surgical excision followed by cold atmospheric plasma treatment. The plasma technology substitutes for additional surgical exploration and provides a non-mechanical method to eliminate residual cells that mechanical means cannot detect or remove.
2Reliability
If radiation therapy is used to treat soft tissue sarcoma, then tumor control is improved, but tissue damage and side effects increase
Solution Approach 1:
The patent changes the physical and chemical parameters of the treatment by using cold atmospheric plasma with specific gas compositions (oxygen, nitrogen, argon) and power settings (e.g., 120W) to achieve tumor cell destruction through reactive oxygen species and nitric oxide generation rather than through ionizing radiation, thereby avoiding radiation-induced tissue damage.
Solution Approach 2:
Cold atmospheric plasma generates high concentrations of reactive oxygen species including singlet oxygen, superoxide anions, and hydroxyl radicals that act as strong oxidants to destroy cancer cells. This oxidative mechanism provides tumor control through a different biochemical pathway than radiation, reducing cumulative tissue damage while maintaining efficacy.
3Reliability
If chemotherapy is administered to treat soft tissue sarcoma, then systemic tumor control is improved, but toxicity and side effects increase
Solution Approach 1:
The patent applies treatment with locally different properties by using cold atmospheric plasma that generates site-specific reactive species concentrations. The plasma can be applied directly to surgical margins and tumor beds, creating localized high concentrations of cytotoxic reactive oxygen and nitrogen species without systemic distribution, thereby achieving local tumor control without systemic chemotherapy toxicity.
4Reliability
If cold atmospheric plasma is applied to treat sarcoma, then tumor cell viability is reduced, but treatment time and power requirements must be optimized
Solution Approach 1:
The patent employs dynamic control of plasma treatment parameters including adjustable power settings (e.g., 120W), variable treatment durations (e.g., 7 minutes), and modifiable gas flow rates. The system allows real-time adjustment of these parameters based on tissue response and treatment progress, enabling optimization of cell killing efficacy while managing treatment complexity through flexible, adaptive control rather than fixed protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Effectively reduces sarcoma cell viability and enhances treatment outcomes by arresting cell cycle progression and inducing apoptosis, offering a minimally invasive approach with reduced tissue damage.
Implementation Method 1
The unique chemical and physical properties of cold atmospheric plasmas enable their numerous recent applications in biomedicine
Implementation Method 2
Cold atmospheric plasma (CAP) reduces sarcoma cell viability in a time- and power-dependent manner by arresting cell cycle progression and inducing apoptosis
Data Source
AI summary
A method for applying cold atmospheric plasma treatment to target tissue comprising the steps of treating a patient with a pharmaceutical for suppressing apolipoprotein E genes, selecting through a graphical user interface a particular soft tissue sarcoma cell line associated with target tissue, retrieving, with the computing device, settings data associated with the selected soft tissue sarcoma cell line from a database of cell line data and associated settings data in a storage, and applying, with the computing device, the retrieved settings data to a cold atmospheric plasma system.